CSF2 and melanoma: The US Food and Drug Administration (FDA) approved in 2015 Talimogene laherparepvec (T-VEC), an attenuated Herpes Simplex Virus 1 (HSV-1) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) for treating unresectable lesions in melanoma patients post-surgery [38].